Akebia doses first patient in Phase 2 kidney disease trial

September 14, 2026 8:02 AM

Akebia Therapeutics (Nasdaq: AKBA) announced that the first patient has been dosed in a Phase 2 basket trial evaluating ebribafusp ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found